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Frequently, treatment of patients with non-small celllung cancer with tyrosine kinase inhibitors is stopped
because of new or progressive bone metastases. Osteoblas-
tic response is considered a healing reaction during effec-
tive systemic therapy, defined by osteoblastic demarcation
of preexisting or “new” bone lesions, whereas disease
response can be identified in other tumor locations.1 In this
study, we describe three patients with non-small cell lung
cancer harboring sensitizing epidermal growth factor re-
ceptor (EGFR) mutations with osteoblastic responses dur-
ing disease control by tyrosine kinase inhibitor treatment.
PATIENT 1
This 47-year-old woman, former smoker, was diag-
nosed with stage IV adenocarcinoma (EGFR exon19 del)
of the lung with pulmonary, hepatic, and osseous metas-
tases. After five cycles of platinum-containing chemother-
apy plus radiotherapy (right shoulder, thoracic spine, and
both femurs), progressive hepatic and osseous metastasis
occurred. Gefitinib was started, and 8 weeks later, com-
puted tomography (CT) confirmed a partial response in
lung and liver. Simultaneously, progressive demarcation of
a preexisting osteoblastic lesion in the left iliac bone could
be identified as possible sign of response (Figures 1A, B).
Six months later, when progressive disease was diagnosed
in lung, liver, and axillary lymph nodes, the lesion in the
left iliac bone showed less sclerosis and more lytic areas
(Figures 1B, C).
PATIENT 2
This 62-year-old woman with a 4 pack-year history of
smoking presented with stage IV adenocarcinoma (EGFR
exon19 del) of the lung involving the middle lobe, the sixth
cervical vertebra, and the left ilium. Bisphosphonate therapy was
started. After chemotherapy with carboplatin/gemcitabine (pro-
gressive disease) and docetaxel/vinorelbine (stable disease), er-
lotinib was started because of bone marrow toxicity. Seven
weeks later, a significant reduction of the primary tumor, the
lymphangiosis, and pleural effusion was observed. Accordingly,
progressive demarcation of an osteoblastic lesion in vertebral
body Th10 (Figures 2A, B) could be detected as a possible sign
of response.
PATIENT 3
This 59-year-old woman, never smoker, with stage
IB adenocarcinoma (EGFR exon19 del) of the lung unde-
rwent a lobectomy of the right lower lobe (R0 resection).
Nine months later, she suffered from a relapse invol-
ving lung, mediastinum, and bone. Bisphosphonate ther-
apy and chemotherapy were started. After failure of
carboplatin/etoposide plus radiotherapy (mediastinum,
vertebral bodies Th4 –Th7) as well as gemcitabine/do-
cetaxel, treatment with erlotinib was started. CT 6 weeks
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FIGURE 1. A, Baseline computed tomography (CT) before therapy with gefitinib shows an osteoblastic metastasis in the
left iliac bone (arrow). B, Restaging CT 8 weeks after initiation of gefitinib therapy demonstrates progressive demarcation
of the preexisting osteoblastic lesion in the left iliac bone (arrow). C, CT 6 months later at progression illustrates in-
creased osteolysis in the former blastic area (arrow) compared with the baseline CT, shown in A, paralleling the overall
tumor progression.
FIGURE 2. A, Baseline computed tomography
before treatment with erlotinib shows an osteo-
blastic lesion in Th10. B, Corresponding to the
clinical benefit after 7 weeks of erlotinib ther-
apy, healing reaction of the osteoblastic lesion
in Th10 is shown. The size of the lesion is not
necessarily increased, but sclerosis is markedly
amplified.
FIGURE 3. A, Baseline computed tomography before start of erlotinib therapy shows an insignificant vertebra Th11. B,
“New” osteoblastic lesions in Th11 are shown in comparison with the baseline imaging 3 months after partial response to ty-
rosine kinase inhibitor treatment had been documented while the patient had still stable disease. C, At overall progression 5
months later, an enlargement of the osteoblastic lesions in Th11 could be identified. Note the blurry edges of the osteoblastic
lesions at this time point.
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later revealed a partial response along with unchanged
bone metastases. Follow-up CT performed 3 months later
confirmed stable disease and showed new osteoblastic
lesions in Th11 (Figures 3A, B) possibly indicating a
delayed response to erlotinib in these locations. The next
follow-up 5 months later documented progressive disease
in the lung and enlargement of the osteoblastic lesions in
Th11, which appeared with more blurry edges at this time
point (Figure 3C).
This report demonstrates that the time course of osteo-
blastic response can vary considerably between patients and
that assessment of bone metastasis based on formal radiologic
criteria alone is not recommended. Instead, the radiologic
interpretation of metastatic bone disease should always in-
clude the full clinical picture to avoid discontinuation of an
actually effective treatment especially when disease control
in other tumor locations can be identified.
ACKNOWLEDGMENTS
RKT is supported by the Deutsche Krebshilfe (grant
107954), by the Fritz-Thyssen-Stiftung (grant 10.08.2.175),
and by the NGFNplus-program of the German Ministry of
Science and Education (BMBF, grant 01GS08100). The Lab-
oratory of Translational Cancer Genomics (LTCG) is funded
by the Deutsche Krebshilfe as part of the Centers of Excel-
lence in Oncology Program.
REFERENCE
1. Stattaus J, Hahn S, Gauler T. Osteoblastic response as a healing
reaction to chemotherapy mimicking progressive disease in patients
with small cell lung cancer. Eur Radiol 2009;19:193–200.
Journal of Thoracic Oncology • Volume 5, Number 3, March 2010 Osteoblastic Responses in EGFR-Mutated NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 409
